紫杉醇协同肿瘤坏死因子相关凋亡诱导配体抑制胶质瘤细胞活性的探讨
Experimental research on biological activities of glioma cells inhibited by TRAIL in combination with paclitaxel

DOI: 10.6040/j.issn.1671-7554.0.2015.036

Keywords: 紫杉醇,肿瘤坏死因子相关凋亡诱导配体,胶质瘤,U251细胞,凋亡,
Glioma,U251 cells,Paclitaxel,TNF-related apoptosis-inducing ligand,Apoptosis

Full-Text   Cite this paper   Add to My Lib

Abstract:

References

[1]	Gretney E, Takeda K, Smyth MJ. Cancer: novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway[J]. Int J Biochem Cell Biol, 2007, 39(2): 280-286.
[2]	Tu LX, Wu YO, Zhang LJ. Experimental study on apoptosis of SGC-7901 cell induced by TRAIL combined with paclitaxel[J]. Chinese Journal of Immunology, 2012, 28(4): 308-311.
[3]	Huang T, Li XH, Li XC, et al. Study on the apoptosis of osteosarcoma cell induced by combination of TRAIL and Paclitaxel[J]. China Journal of Modern Medicine, 2013, 23(2): 42-45.
[4]	Tan QP, Liu Y, Qiu YZ, et al. Synergistic interactions of TRAIL and paclitaxel on the nasopharyngeal carcinoma cell lines in vitro[J]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, 2012, 26(7): 319-322.
[5]	Talibi SS, Aweid B, Aweid O. Prospective therapies for high-grade glial tumours: A literature review[J]. Ann Med Surg(Lond), 2014, 3(3): 55-59.
[6]	Khan M, Bi Y, Qazi JI, et al. Evodiamine sensitizes U87 glioblastoma cells to TRAIL via the death receptor pathway[J]. Mol Med Rep, 2015, 11(1): 257-262.
[7]	Ismail B, Fagnere C, Limami Y, et al. 2'-Hydroxy-4-methylsulfonylchalcone enhances TRAIL-induced apoptosis in prostate cancer cells[J]. Anticancer Drugs, 2015, 26(1): 74-84.
[8]	Xu F, Wang F, Yang T, et al. Differential drug resistance acquisition to doxorubicin and paclitaxel in breast cancer cells[J]. Cancer Cell Int, 2014, 14(1): 538.
[9]	van Roosmalen IA, Quax WJ, Kruyt FA. Two death-inducing human TRAIL receptors to target in cancer: similar or distinct regulation and function?[J]. Biochem Pharmacol, 2014, 91(4): 447-456.
[10]	Zhan C, Wei X, Qian J, et al. Co-delivery of TRAIL gene enhances the anti-glioblastoma effect of paclitaxel in vitro and in vivo[J]. J Control Release, 2012, 160(3): 630-636.
[11]	Yoshida T, Zhang Y, Rivera RL, et al. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells[J]. Mol Cancer Res, 2009, 7(11): 1835-1844.
[12]	Sun X, Pang Z, Ye H, et al. Co-delivery of pEGFP-hTRAIL and paclitaxel to brain glioma mediated by an angiopep-conjugated liposome[J]. Biomaterials, 2012, 33(3): 916-924.
[13]	Holland PM. Death receptor agonist therapies for cancer, which is the right TRAIL?[J]. Cytokine Growth Factor Rev, 2014, 25(2): 185-193.
[14]	Hunter TB, Manimala NJ, Luddy KA, et al. Paclitaxel and TRAIL synergize to kill paclitaxel-resistant small cell lung cancer cells through a caspase-independent mechanism mediated through AIF[J]. Anticancer Res, 2011, 31(10): 3193-3204.
[15]	Qiu B, Sun X, Zhang D, et al. TRAIL and Paclitaxel synergize to kill U87 cells and U87-derived stem-like cells in vitro[J]. Int J Mol Sci, 2012, 13(7): 9142-9156.
[16]	Wang F, Lin J, Xu R. The molecular mechanisms of TRAIL resistance in cancer cells: help in designing new drugs[J]. Curr Pharm Des, 2014, 20(42): 6714-6722.

Full-Text